Grantee Name: Jean-Luc van Laethem
Organization: Hospital Erasme, Universit Libre de Bruxelles
Focus Area: Therapy Optimization
Funding Year: 2021
Funding Scheme: ACF
Project period: 4 years
This trial is a phase II-study testing the combination of mFOLFIRINOX, a chemotherapy already used to treat pancreatic cancer today, and high-dose SBRD (Stereotactic Body Radiation Therapy), followed by surgery and adjuvant chemotherapy (if appropriate) in patients with an adenocarcinoma who have not undergone previous treatment for pancreatic cancer. 256 patients will be enrolled in at least 10 Belgian hospitals. The key objectives are to assess efficacy of treatment in improving success rate of the surgical intervention and increases the disease-free survival of patients.
The trial is funded by Anticancer Fund and Rising Tide Foundation within a joint effort aimed at supporting high impact clinical trials testing novel strategies in the treatment of pancreatic ductal adenocarcinomas (PDAC) and/or biliary tract cancer (BTC*). Additional funds will be provided by the King Baudouin Foundation and Les Amis de L’Institut Bordet.